Oxymetholone 50mg/tab 100 Tabletten by Kim Pharma

Usage

1. Establish baseline bloods before cycle start.: Obtain ALT, AST, haematocrit, fasting lipids, and testosterone reference values at least 72 hours before the induction phase begins — these values anchor your biomarker checkpoints throughout the cycle.
2. Begin induction phase at 25–50 mg daily depending on baseline hepatic enzyme status.: Practitioners with ALT within the lower half of the reference range may begin at the full 50 mg; those at the upper third should open at 25 mg and reassess at day 14.
3. Run biomarker checkpoint at the phase-one/phase-two boundary (end of week 2).: If ALT and AST remain below three times the upper reference limit and haematocrit is below 54%, proceed to peak phase. If either threshold is breached, hold at induction dose or discontinue.
4. Maintain peak phase at 50 mg daily for two weeks (weeks 3–4).: Take the single 50 mg tablet at a consistent daily time, with a small mixed meal to optimise gastric tolerance without significantly delaying absorption relative to training windows.
5. Execute a five-day stepdown exit phase at 25 mg daily.: Split one tablet as evenly as possible or hold half a tablet to reduce abrupt androgenic withdrawal; this eases endogenous HPTA reactivation before PCT commences.
6. Initiate PCT on day one of the post-cycle window.: Begin standard SERM-based post-cycle therapy immediately after the exit phase concludes; do not delay PCT start based on subjective energy or mood signals.

Warnings

Frequently asked questions

How does modern cycle architecture integrate Oxymetholone compared to older flat-dose approaches?

Modern cycle architecture assigns Oxymetholone to specific time-bound phases — induction, peak, and exit — rather than running a flat dose across an open-ended duration. This structure limits continuous exposure to four weeks at full dose, which evidence from clinical hepatotoxicity studies associates with a more manageable ALT/AST trajectory. Older unstructured protocols lacked defined exit phases, increasing cumulative hepatic burden.

At which point in a cycle do most modern protocols introduce Oxymetholone?

Most modern protocols introduce Oxymetholone at cycle onset during the induction phase, typically within the first two weeks, to establish early anabolic and erythropoietic momentum while longer-acting compounds are still building toward therapeutic plasma levels. Some practitioners delay introduction to the cycle's midpoint as a peak-phase intensifier, depending on the overall stack and objective.

What is the recommended cycle length for Oxymetholone under current evidence-informed protocol design?

Current evidence-informed protocol design supports a four-week active window covering all three phases — induction, peak, and structured exit — with a biomarker checkpoint at the phase two transition. Extending beyond four weeks of full-dose exposure is associated with non-linear hepatic enzyme elevation in the clinical literature, which is why modern frameworks treat four weeks as the functional upper boundary.

Why is 50 mg per tablet the preferred concentration for structured cycle planning?

At 50 mg per tablet, each unit corresponds directly to the standard full daily dose used in most modern cycle protocols, eliminating the need to split or combine tablets between phases. This one-to-one dose-to-tablet ratio reduces administration error at phase transition points and is the highest concentration available in this product group, giving practitioners maximum flexibility within a single-tablet daily format.

Can a 100-tablet pack of Kim Pharma Oxymetholone cover a complete modern three-phase cycle?

Yes. A 100-tablet pack at 50 mg per tablet covers a full four-week peak phase at one tablet daily — 28 tablets — with approximately 72 tablets remaining to support a longer induction phase or to accommodate a second cycle. The pack size is intentionally surplus to a single four-week block, providing a buffer for titration at phase entry without requiring a supplementary purchase. (2) angle_used

Manufacturer

Kim Pharma's pricing approach for its oral anabolic tablet range reflects a deliberate market positioning decision: keeping per-tablet costs accessible without reducing the analytical verification standards that underpin batch release. For a 100-tablet pack of Oxymetholone at 50 mg per unit, this means the cost per daily dose at standard protocol quantities remains within reach of athletes running recurring structured cycles — a category of user whose annual compound spend accumulates across multiple consecutive purchasing decisions rather than a single purchase. Affordability at the pack level does not come at the expense of HPLC potency confirmation or LAL endotoxin screening; both remain applied on every batch before any stock is released to the distribution network. Kim Pharma achieves this cost structure through high-volume tableting batch scheduling, which distributes fixed analytical and quality assurance overheads across a larger unit count per production run — keeping the per-tablet price competitive while preserving the verification layer that makes biomarker-based cycle monitoring meaningful.